Skip to main content

Table 1 Clinical and laboratory characteristics of patients with KS-IRIS- and non-KS-IRIS

From: Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma

Patient characteristics

IRIS-KS N = 35 (39%) (CI95% 29–50)

Non-IRIS-KS (N = 54) (60.6%) CI 95% 50–71)

All patients (N = 89)

p

Mean age ± 2 SD (years)

32 ± 7

36 ± 8

35 ± 8

0.01

Weeks from HIV diagnosis to cART (median, IQR)

10 (5‒33)

10 (6‒30)

10 (6‒30)

0.24

Median baseline CD4+ cells/mm3 (IQR)

82 (30–140)

110 (36‒230)

91 (34–204)

0.43

Median CD4+ cells/mm3 12 weeks after cART initiation (IQR)

212 (89–357)

308 (159–391)

249 (144–387)

0.28

ACTG staging

 S0T0

0

7 (13%)

7 (7.8%)

0.18

 S1T0

1 (4.4%)

11 (20%)

12 (13.5%)

 S0T1

19 (54%)

18 (33%)

37 (41.5%)

 S1T1

15 (42.8%)

18 (33%)

33 (37%)

Deaths ACTG staging

 S0T0

0

0

0

0.3

 S1T0

0

0

0

 S0T1

5 (12.8%)

1 (1.1%)

6 (0%)

 S1T1

4 (10.2%)

4 (7.4%)

8 (9%)

Median HIV-RNA copies/mm3 at baseline. (IQR)

240,000 (106,000–612,000)

84,731 (31,300–250,000)

131,818 (57,200–361,124)

0.02

HIV-RNA at follow-upa: copies/mm3

 Number of patients

31

50

81

0.02

 <100

25 (80.6)

48 (96)

73 (90.1)

 101‒1000

4 (12.91)

1 (2)

5 (6.2)

 1001‒50,000

1 (3.2)

1 (2)

2 (2.5)

 >50,000

1 (3.2)

0

1 (1.2)

Antiretroviral therapy—No (%)

    

 NNRTI

20 (57)

25 (46)

45 (50.6)

0.36

 PI

15 (42)

28 (51.8)

43 (48.3)

 3 NRTI

0

1 (1.85)

1 (1)

Mucosal involvement—No (%)

27 (77)

35 (65)

62 (70)

0.25

Confluent/disseminated skin lesions—No (%)

25 (71)

25 (46)

50 (56)

0.01

Lymphedema—No (%)

15 (43)

14 (26)

29 (32)

0.09

Deaths—No (%)

5 (33%)

2 (14)

7 (24)

0.39

Gastrointestinal involvement—No (%)b

14 (61)

10 (37)

24 (48)

0.16

Deaths %

6 (43%)

4 (40%)

10 (42%)

0.41

Pulmonary involvement—No (%)

22 (63)

9 (17)

31 (35)

<0.001

Deathsc

8 (38%)

2 (22%)

10 (30%)

0.45

Platelets at first visitd

 >100,000/mm3

29 (85%)

46 (85)

75 (85%)

0.62

 50‒100,000

2 (6%)

4 (7%)

6 (7%)

 <50,000

3 (8.9%)

4 (7%)

7 ((8%)

Platelets at follow-upe

 >100,000/mm3

20 (64%)

48 (96%)

68 (84)

0.0003

 50‒100,000

4 (13%)

2 (4)

6 (7)

 <50,000

7 (23%)

0

7 (8.6)

Deaths first year

9 (26%)

5 (9.3%)

14 (15.7)

0.07

KS attributable deaths

8 (89%)

0

8 (57%)

  1. IQR interquartile range, cARTc combined antiretroviral therapy, HIV Human immunodeficiency syndrome, NS not significant, SD standard deviation, NNRTI Non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, NRTI nucleoside reverse transcriptase inhibitor
  2. aViral load at follow-up was measured between weeks 12 and 16 after initiation of cART; four patients died before follow-up of viral load determination
  3. bEndoscopy was performed in 50 patients (21 Immune reconstitution inflammatory syndrome-Kaposi’s sarcoma [IRIS-KS] and in 29 with non-IRIS)
  4. cMortality for pulmonary involvement was evaluated in the first 48 weeks after cART initiation
  5. dComplete blood counts (CBC) were not performed at the first visit in 2 patients
  6. eIn five patients, CBC was not performed at follow-up
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us